Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
Alvotech (NASDAQ: ALVO) priced a $152 million public offering of 22,666,667 ordinary shares at $3.75 each, with an underwriters’ 30-day option to buy up to 3,400,000 more shares. Expected gross proceeds are about $85 million, or $98 million with the option. A concurrent private placement will sell 17,826,666 shares for about $67 million. Net proceeds will fund biosimilar development and corporate purposes.
Dilutive equity financing at a fixed price; near-term pressure risk balanced by funding runway for pipeline and corporate needs.
Alvotech priced a $152M public offering plus concurrent private placement at $3.75/share to fund biosimilar development and working capital.
Likely near-term downside/volatility around issuance/closing, with potential stabilization if investors view proceeds as extending development runway.
Background
Alvotech previously announced an underwritten public offering and is now pricing it, alongside a concurrent exempt private placement to EEA qualified investors.
Why it matters
The key new information is the final offering price ($3.75/share), share counts, total gross proceeds ($152M; $165M with option), and intended use of proceeds (biosimilar development, working capital, and corporate purposes).
Market relevance
A priced equity raise with defined proceeds and closing windows is a direct, tradable catalyst for the issuer, primarily via dilution and funding-runway expectations.
Market effects
Biosimilars/biotech names may see read-across on equity financing appetite and dilution risk, but this is company-specific rather than a sector-wide regulatory/clinical catalyst.
Limited direct regional spillover; the private placement is targeted to EEA qualified investors, while the public offering is in the US.
Proceeds are earmarked for global biosimilar development and corporate purposes, but the disclosure is not tied to a specific global regulatory milestone.
Alternative perspectives
If the market had been discounting funding risk, the $152M gross proceeds could reduce balance-sheet uncertainty and support the stock after initial dilution selling.
The offering includes an underwriter option (up to 3.4M additional shares), and the private placement is not contingent on the public offering—timing and execution could affect short-term supply/demand dynamics into the closing dates.
Key entities
- companyAlvotech
NASDAQ-listed biosimilars company pricing a $152M public offering and concurrent private placement.
- financial_advisorBofA Securities
Joint book-running manager for the offering.
- financial_advisorJefferies
Joint book-running manager for the offering.
- financial_advisorEvercore ISI
Joint book-running manager for the offering.
